A team led by researchers from UT Southwestern Medical Center and a university in South Korea has identified a subset of brain cells whose activation may be partially responsible for the effects of a popular class of weight loss drugs that includes semaglutide and tirzepatide. Their findings, published in Science, could eventually help scientists optimize the efficacy of these drugs, known as glucagon-like peptide-1 receptor agonists (GLP-1RAs).
